AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
On July 11, 2025, Medtronic's stock rose by 3.11% in pre-market trading, reflecting positive market sentiment and investor confidence in the company's recent strategic moves and financial performance.
Medtronic has recently launched the AiLLIANCE China Edition (ACE) clinical research project in Shanghai, focusing on the local application and value of its AiBLETM digital orthopedic ecosystem. This initiative aims to accelerate the digital transformation of orthopedics, enhance diagnostic and treatment capabilities, and improve healthcare accessibility. The project, involving four leading domestic orthopedic research centers, will systematically evaluate the clinical and health economic value of digital orthopedics, fostering deeper integration of intelligent technology with clinical practice.
In addition to its digital orthopedic advancements,
has made significant strides in its diabetes business. The company has appointed Chad Spooner as the Chief Financial Officer (CFO) of its MiniMed division, effective July 14, 2025. Spooner brings over 25 years of financial management experience in healthcare, consumer, and industrial sectors. His appointment comes as Medtronic plans to spin off its diabetes business into an independent publicly traded company, MiniMed. Spooner's role will be crucial in building the financial infrastructure for the new entity, supporting its strategic transformation and long-term growth objectives.
Get the scoop on pre-market movers and shakers in the US stock market.

Dec.19 2025

Dec.19 2025

Dec.19 2025

Dec.19 2025

Dec.19 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet